GRAFT-VERSUS-HOST-DISEASE
Clinical trials for GRAFT-VERSUS-HOST-DISEASE explained in plain language.
Never miss a new study
Get alerted when new GRAFT-VERSUS-HOST-DISEASE trials appear
Sign up with your email to follow new studies for GRAFT-VERSUS-HOST-DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Lower drug dose may prevent transplant complications just as well
Disease control CompletedThis study tested whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers or disorders. 35 adults with a related donor took part. The lower dose worked as well as the standard dose…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated May 26, 2026 07:45 UTC
-
Blood filtering with light may stop transplant rejection
Disease control CompletedThis study tested whether a procedure called extracorporeal photophoresis (ECP) — where a patient's blood is treated with light outside the body — could prevent graft-versus-host disease (GVHD) in 158 people receiving stem cell transplants for blood cancers. GVHD is a serious com…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: NA • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
Stem cells show promise for deadly transplant complication
Disease control CompletedThis study tested a stem cell product called Prochymal in 11 patients with severe graft-versus-host disease (GVHD) that did not respond to standard treatments. The goal was to see if the stem cells could safely improve or resolve GVHD symptoms. The approach involved infusing adul…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: Mesoblast, Inc. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug shows promise in preventing transplant complication
Disease control CompletedThis small pilot study tested whether the drug belimumab (Benlysta) could safely prevent chronic graft-versus-host disease (GvHD) in 10 adults who had a stem cell transplant for blood cancer. Chronic GvHD is a serious condition where donor immune cells attack the patient's body. …
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New hope for GVHD patients who failed first drug
Disease control CompletedThis study tested a drug called nilotinib in 65 adults with chronic graft-versus-host disease (GVHD), a complication after a stem cell transplant where donor cells attack the patient's body. Participants had already tried imatinib without success. The goal was to see if nilotinib…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug combo shows promise in preventing transplant complications
Disease control CompletedThis early-phase study tested whether adding a drug called BMS-986004 (which blocks CD40-L) to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD is a s…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New hope for stem cell transplant patients: drug targets stubborn GvHD
Disease control CompletedThis study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD), a condition where donor immune cells attack the recipient's body after a stem cell transplant. Participants had GvHD that did not improve with standard treatments. They took p…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New imaging tracer shows promise for spotting GVHD without biopsy
Knowledge-focused CompletedThis early-phase study tested a new imaging tracer called [18F]F-AraG in 9 patients to see if it could detect graft-versus-host disease (GVHD) after a stem cell transplant. The tracer highlights activated immune cells that cause GVHD, and the scans were compared with standard bio…
Matched conditions: GRAFT-VERSUS-HOST-DISEASE
Phase: PHASE1 • Sponsor: CellSight Technologies, Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 07:42 UTC